Historical Valuation
NOVOSENSE (02676) is now in the Overvalued zone, suggesting that its current forward PS ratio of 7.22 is considered Overvalued compared with the five-year average of -384.88. The fair price of NOVOSENSE (02676) is between 97.68 to 112.71 according to relative valuation methord. Compared to the current price of 140.10 USD , NOVOSENSE is Overvalued By 24.3%.
Relative Value
Fair Zone
97.68-112.71
Current Price：140.10
24.3%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
NOVOSENSE (02676) has a current Price-to-Book (P/B) ratio of 2.60. Compared to its 3-year average P/B ratio of 3.04 , the current P/B ratio is approximately -14.40% higher. Relative to its 5-year average P/B ratio of 3.04, the current P/B ratio is about -14.40% higher. NOVOSENSE (02676) has a Forward Free Cash Flow (FCF) yield of approximately -3.42%. Compared to its 3-year average FCF yield of -3.66%, the current FCF yield is approximately -6.64% lower. Relative to its 5-year average FCF yield of -3.66% , the current FCF yield is about -6.64% lower.
P/B
Median3y
3.04
Median5y
3.04
FCF Yield
Median3y
-3.66
Median5y
-3.66
Performance Decomposition
AI Analysis for 02676
1Y
3Y
5Y
Market capitalization of 02676 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 02676 in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is 02676 currently overvalued or undervalued?
NOVOSENSE (02676) is now in the Overvalued zone, suggesting that its current forward PS ratio of 7.22 is considered Overvalued compared with the five-year average of -384.88. The fair price of NOVOSENSE (02676) is between 97.68 to 112.71 according to relative valuation methord. Compared to the current price of 140.10 USD , NOVOSENSE is Overvalued By 24.30% .
What is NOVOSENSE (02676) fair value?
02676's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of NOVOSENSE (02676) is between 97.68 to 112.71 according to relative valuation methord.
How does 02676's valuation metrics compare to the industry average?
The average P/S ratio for 02676's competitors is , providing a benchmark for relative valuation. NOVOSENSE Corp (02676) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for NOVOSENSE (02676) as of Jan 09 2026?
As of Jan 09 2026, NOVOSENSE (02676) has a P/B ratio of 2.60. This indicates that the market values 02676 at 2.60 times its book value.
What is the current FCF Yield for NOVOSENSE (02676) as of Jan 09 2026?
As of Jan 09 2026, NOVOSENSE (02676) has a FCF Yield of -3.42%. This means that for every dollar of NOVOSENSE’s market capitalization, the company generates -3.42 cents in free cash flow.
What is the current Forward P/E ratio for NOVOSENSE (02676) as of Jan 09 2026?
As of Jan 09 2026, NOVOSENSE (02676) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of NOVOSENSE’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for NOVOSENSE (02676) as of Jan 09 2026?
As of Jan 09 2026, NOVOSENSE (02676) has a Forward P/S ratio of 7.22. This means the market is valuing 02676 at $7.22 for every dollar of expected revenue over the next 12 months.